12 September - 15 September 2027

24th SCI-RSC Medicinal Chemistry Symposium

Organised by:

SCI’s Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector

Churchill College, Cambridge, UK

Register your interest
Synopsis
The organisers invite you to the 24th SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry. Reflecting current trends in medicinal chemistry and pharmaceutical research, the scientific programme will feature lectures on the full range of drug targets and drug discovery approaches.
Workshop
The workshop is based on an interactive, team-based game that allows you to explore various aspects of the drug discovery process. Delegates will work together in teams with peers from other organisations and the learning experience will be facilitated by a dedicated and diverse team of experienced professional medicinal chemists from across the pharmaceutical industry. This is a great way to accelerate your learning curve in medicinal chemistry, learning from your peers and our experts and it’s a lot of fun to play.
Attendees

This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process.
The separate workshop will be of interest to early career scientists, typically with five years or fewer post-graduate experience in medicinal chemistry.


Confirmed talks

Toward pandemic-ready oral antivirals: Discovery of GS-1701,
a non-boosted pan-beta-coronavirus Mpro inhibitor
Stephen Ammann, Gliead, USA.

Discovery of AZD4956, a potent and selective inhibitor of DNA polymerase theta, a clinical
candidate for treatment of HRR-deficient tumors in combination with saruparib
Bernard Barlaam, AstraZeneca, UK

AMR Drug Discovery at the Holistic Drug Discovery and Development Centre
(H3D) at the University of Cape Town - An Overview and Future Perspectives
Grant Boyle, H3D, Republic of South Africa

Discovery of the Brain Penetrant NLRP3 inhibitor RG6434
Stefanie Mesch, Roche, Switzerland

Discovery and development of Setidegrasib (ASP3082), a first-in-class
KRAS G12D degrader for solid tumors
Takanori Koike, Astellas, Japan

Controlling Biological State with Small Molecules
Angela Russell, University of Oxford, UK

The discovery of novel orally bioavailable NS2BNS3 dengue inhibitors
Ed Griffen, MedChemica, UK

From fragment to lead: the discovery of novel, selective, small molecule inhibitors of Bfl-1
Arnaud Le Tiran, a, France

DNA Damage Response Inhibitor Mono and Dual Payload Antibody-Drug Conjugates
Robert Heald, Artios, UK

UK DDU384: From Hit Identification to a new Preclinical Candidate for Tuberculosis
Laura Cleghorn, Drug Discovery Unit, University of Dundee, UK

Optimisation of an Oral CNS Penetrant TRPM3 Inhibitor:
From HTS to an in vivo Capable Tool Compound
Alex Preston, GSK, UK


Call for posters
Poster abstracts are invited from the whole field of medicinal chemistry.
Those presenting a poster may also elect to advertise their poster via an
oral presentation of a single-slide ‘flash’ poster. Please download a template
from the website (closing date to be confirmed).


Programme

The programme will be announced in due course.


Exhibition and sponsorship
Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.

The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition rate will include two stand staff and daytime refreshments.  

For further details, please contact conferences@soci.org


Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.


Venue and Contact

Churchill College

Storey's Way 
Cambridge 
CB3 0DS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Booking Process/Deadlines

Booking terms and conditions


Partners

Organising committee
Cinzia Bordoni, Jazz Pharmaceuticals 
John Cumming, Roche 
 Daniel O Donovan, AstraZeneca 
 Mark Healy, Novartis 
 Katherine Jones, Charles River 
 Joanne Pinder, Vertex 
 Jamie Scott, AstraZeneca 
 Chris Swain, Cambridge MedChem Consulting 
 Francis Wilson, Avacta Therapeutics